Compare Sana Biotechnology Inc (SANA) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while Vanguard Information Technology Index Fund ETF trades at $128 (market cap $170.20B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 203.4× Sana Biotechnology Inc's market cap, and Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Vanguard Information Technology Index Fund ETF for 129 Days on average.
| SANA | VGT | |
|---|---|---|
Market Cap | $836.71M | $170.20B |
Volume | 4,507,444 | 5,132,883 |
Sector | Health | — |
52-Week High | $5.92 | $129.79 |
52-Week Low | $2.68 | $83.59 |
Typical Hold Time | 23 Days | 129 Days |
Enterprise Value | $749.96M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
VGT trades at $127.78, down 1.23% today but maintains a bullish technical outlook with strong moving average signals. The ETF, focused on U.S. technology stocks, has delivered exceptional historical returns, averaging over 17% annually. Recent news highlights its low expense ratio and concentration in tech giants like Nvidia, Apple, and Microsoft. A dividend of $0.15 is scheduled for September 2026.
Long-term growth prospects remain favorable given tech sector dominance and AI momentum, but risks include sector concentration, valuation concerns, and potential AI slowdown. Institutional ownership is increasing, with firms like Baird Financial raising stakes significantly. The current price near pivot point resistance at $128 suggests near-term consolidation before potential breakout.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
